Demographic Shift and Healthcare Demand - The world is experiencing a significant demographic shift with populations aging rapidly, where individuals aged 60 and older outnumber children under five for the first time in 2020, projected to exceed 2 billion by 2050 [2] - The U.S. population aged 65 and older is expected to nearly double by 2050, with those aged 85 and older projected to triple by 2060 [2] Geriatric Care Market Growth - The global geriatric care services market, valued at $1 trillion in 2022, is expected to more than double by 2033, driven by growth in pharmaceuticals, medical devices, long-term and home-based care, and digital health solutions [3] Healthcare Challenges in the U.S. - Mortality rates among seniors have increased by 4.5% annually, with a 50% rise for those aged 85 and older; Alzheimer's and dementia-related deaths are up 40% [4] - Hospital utilization is surging, with admissions rising by 25%, average stay lengthening, readmissions increasing by 20%, and emergency visits soaring by 40% [4] Pharmaceutical and Device Companies' Response - Pharmaceutical firms like Roche and Novo Nordisk are focusing on high-demand areas, while device makers such as Edwards Lifesciences and Stryker are advancing tools for chronic disease management [5] Digital Health Innovations - Digital health is transforming elder care with AI-powered diagnostics, remote monitoring, and wearables, leading to better outcomes and new revenue models [6] - The demand for home care is rising as more seniors choose to age at home, although a projected shortage of 2.3 million long-term care workers by 2030 poses challenges [6] Financial Trends in Senior Care - U.S. senior care spending exceeded $1 trillion in 2022 and could double by 2040, emphasizing the need for value-based models and efficient chronic disease management [7] Roche's Strategic Initiatives - Roche is advancing Alzheimer's diagnostics with the Elecsys Amyloid Plasma Panel, showing 91% sensitivity and 96.2% negative predictive value, and has announced a $50 billion investment in U.S. operations over five years [8][9] Novo Nordisk's Regulatory Wins - Novo Nordisk's Ozempic received FDA approval for reducing kidney disease progression and cardiovascular death in adults with Type 2 diabetes, and the company is investing €2.34 billion to upgrade its production facility in Italy [10][11] Edwards Lifesciences' Innovations - Edwards Lifesciences is focusing on aortic stenosis care, with new data showing early treatment reduces costs and improves outcomes; TAVR sales reached $1.05 billion in Q1 2025 [12][13] Stryker's Market Penetration - Stryker is making strategic investments in senior healthcare, enhancing capabilities in minimally invasive neurosurgery through acquisitions, and offering products designed to improve outcomes for elderly patients [14][15]

Oh, hey Barbie. There's a new girl on the block and she is not like any other doll on the market. This Barbie wears an adorable blue polka dot top, a ruffled minikirt, and an insulin pump.She is Mattel's first doll with type 1 diabetes. The doll was made in collaboration with a diabetes research organization to make sure all the accessories are accurate. ...

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2025) - Victory Square Technologies Inc. (CSE: VST) (OTC Pink: VSQTF) ("Victory Square" or the "Company"), a venture builder that provides public investors with access to early-stage technology companies, today announced its financial results for the three months ended March 31, 2025, and shared an update on its key business focus areas for the remainder of the year.Q1 2025 Financial Highlights Adjusted Revenue: $6.528MGAAP Revenue: $4.540MCost of Good ...

GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to beco ...

GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board."We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtroni ...

Key Takeaways TNDM launched early U.S. access for t:slim X2 pump compatible with Abbott's FreeStyle Libre 3 Plus sensor. Abbott's Libre 3 Plus sends glucose data every minute to TNDM's t:slim mobile app. TNDM plans to integrate Abbott's future sensors for broader diabetes management solutions.Tandem Diabetes Care, Inc.’s (TNDM) t:slim X2 insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now compatible with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) senso ...

Eli Lilly and Company (NYSE:LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor Relations Conference Call Participants Unidentified Analyst Get started here. Welcome to day 2 of our healthcare conference. The weather is still holding up. Thank God for that. Very pleased to kick off our morning session this morning with Eli Lilly. We have Lucas Montarce, CFO; and Mike Czapar, Sen ...

Core Insights - MannKind Corporation will showcase its inhaled insulin product, Afrezza, at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025, in Chicago [1][5] - Dr. Michael J. Haller will present results from the INHALE-1 clinical trial, focusing on inhaled insulin treatment for children and adolescents aged 4-17 [2][3] - MannKind plans to submit a Supplemental Biologics License Application for a pediatric indication for Afrezza in mid-2025, following the release of topline results from the full pediatric data set in Q2 2025 [5] Company Overview - MannKind Corporation specializes in developing and commercializing inhaled therapeutic products and delivery devices for endocrine and orphan lung diseases [6][7] - The company aims to address serious unmet medical needs through innovative dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [7] Upcoming Events - The ADA's Scientific Sessions will feature a symposium titled "Future Ready," where breakthrough advancements in pediatric Type 1 diabetes care will be discussed [3] - MannKind will host a booth (1617) at the event for scientific exchange and to showcase its products [4]

Deal Overview - Medtronic plc announced its intent to spin off its Diabetes business into a standalone entity, referred to as the New Diabetes Company, to streamline its portfolio and focus on high-margin growth areas [2][3] - The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) [3] Company Focus Post Spin-Off - Post spin-off, Medtronic will concentrate on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies, which together account for over 90% of its total revenues [3][6] - The company aims to accelerate growth through innovation in areas such as pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation [3] Financial Implications - The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market [4] - Medtronic expects its dividend per share to remain unchanged pre- and post-transaction, with no change to its dividend policy [4] Diabetes Segment Performance - The Diabetes segment contributed approximately $2.5 billion in FY25, about 8% of Medtronic's total revenue of $32.4 billion, but has underperformed with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR [7][6] - The segment's operating margin has declined significantly from 30.9% in FY19 to 15.8% in FY25, indicating challenges in profitability [7] Market Challenges - The Diabetes segment has faced multiple headwinds, including FDA regulatory setbacks and increasing competition from agile players like Dexcom and Abbott [8] - Despite a recent rebound with a growth of ~10.7% YoY in FY25, the improvement is insufficient to offset structural challenges [9] Strategic Goals for New Diabetes Company - The New Diabetes Company will focus on creating a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring, and digital health solutions [3][33] - The separation is expected to unlock value for Medtronic and its shareholders, creating a shareholder base more aligned with the financial profile of the New Diabetes Company [12] Company Overview - Medtronic plc is a global healthcare technology leader, operating in over 150 countries and focusing on improving patient outcomes through innovation in various medical technologies [13][32] - The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, addressing a wide range of health conditions [32]

Embecta (EMBC) 2025 Conference June 05, 2025 04:55 PM ET Speaker0 All right. Good afternoon, everyone. My name is Mike Sarcone. I'm an analyst on the US medical supplies and devices team here. And this is the last session for Jefferies twenty twenty five New York Healthcare Conference and this is a fireside chat with MBECTA. And from the company we've got Jake Elgouy, CFO and we're also joined here by Pravesh Kandawal who heads the IR function. So gentlemen, thank you both for being with us today. Speaker1 ...